Justin Walsh
Stock Analyst at Jones Trading
(2.97)
# 1,536
Out of 5,044 analysts
37
Total ratings
42.86%
Success rate
12.65%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $199.33 | -58.36% | 1 | Sep 18, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $109 → $84 | $57.33 | +46.52% | 10 | Sep 16, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.42 | +606.38% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.77 | +218.30% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $9.37 | +220.17% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $79.92 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.09 | +116.11% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $13.62 | +32.16% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $28.96 | +45.03% | 1 | Oct 18, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.87 | +666.55% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.92 | +225.53% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.78 | +318.41% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.84 | +378.35% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.82 | +314.94% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $26.93 | +1,237.05% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.57 | +27,925.48% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.58 | +12,727.09% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $38.15 | -47.58% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.50 | +13,233.33% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.10 | +143.90% | 1 | Jan 19, 2022 |
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $199.33
Upside: -58.36%
Lantheus Holdings
Sep 16, 2025
Maintains: Buy
Price Target: $109 → $84
Current: $57.33
Upside: +46.52%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.42
Upside: +606.38%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.77
Upside: +218.30%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $9.37
Upside: +220.17%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $79.92
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.09
Upside: +116.11%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $13.62
Upside: +32.16%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $28.96
Upside: +45.03%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.87
Upside: +666.55%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.92
Upside: +225.53%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.78
Upside: +318.41%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.84
Upside: +378.35%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $4.82
Upside: +314.94%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $26.93
Upside: +1,237.05%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.57
Upside: +27,925.48%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.58
Upside: +12,727.09%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $38.15
Upside: -47.58%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.50
Upside: +13,233.33%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $4.10
Upside: +143.90%